权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Delaney AIDS Research Enterprise to Cure HIV

德莱尼艾滋病研究企业治愈艾滋病毒

基本信息

批准号：
10469472
负责人：
STEVEN Grant DEEKS
金额：
$ 544.89万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-16 至 2026-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10469472
关键词：
Acquired Immunodeficiency Syndrome Acute Address Aftercare Animal Model Anti-Retroviral Agents Antigen Targeting Apoptotic BCL2 gene Biological CD8-Positive T-Lymphocytes Cell Death Cell Survival Cells Cessation of life Clinical Clinical Trials Clinical Trials Design Cytomegalovirus Vaccines Development Disease remission Event Frequencies Future Genetic Transcription Goals Growth HIV HIV Infections Helper-Inducer T-Lymphocyte Human Immune Immune response Immune system Immunologics Immunotherapy In Vitro Individual Infection Intercept Interruption Investments Lead Lymphoid Tissue Mediating Mission Modeling Monkeys Nature Pathway interactions Persons Pharmaceutical Preparations Population Predisposition Proliferating Proteins Proviruses Recrudescences Regimen Research Research Design Research Personnel Residual state Resistance Resources SIV Sampling Series Signal Transduction Sustainable Development T cell response T-Lymphocyte Testing Therapeutic Therapeutic Studies Viral Viral Antigens Viral Proteins Viremia Virus Work adaptive immune response antagonist antiretroviral therapy base cell killing cohort collaboratory combinatorial design humanized mouse in vitro Model in vivo meetings member mimetics mouse model nonhuman primate preclinical development prevent programs response therapy development treatment optimization viral RNA viral rebound

项目摘要

PROJECT SUMMARY/ABSTRACT The goals of the DARE Collaboratory are to develop a viable combination regimen that reduces the rebound- competent HIV/SIV reservoir during antiretroviral therapy (ART) and/or induces durable control of HIV/SIV in the absence of therapy. Our proposed work is based on two observations made our group. First, we found that virus- specific CD8+ T cells contribute to control of the virus at steady-state. These cells, however, have limited effect during and immediately post-ART. We believe and will seek to prove that effective remission strategies will require organization of a robust innate and adaptive immune response during the earliest stages of virus rebound, effectively intercepting and suppressing viral rebound prior to the massive systemic growth of SIV/HIV that overwhelms, damages and/or evades the immune system. Second, we and others have found that despite virus expression during ART (either naturally or in response to a latency reversal agent), the frequency of infected cells remains stable. We have found that infected cells are relatively resistant to cell death programs. We will develop therapies that render these cells to host-mediated clearance mechanisms, thus resulting in their reduction and perhaps elimination. To achieve our goals, we will (1) characterize in people transcriptionally active cells and proliferating infected cells, focusing on identifying mechanisms for persistence, (2) define in people the earliest immunologic and virologic events post-interruption of ART, focusing on post-treatment controllers, (3) develop in non-human primates (NHPs) a combination regimen that targets the reactivating virus during the immediate post-ART period and results in sustained control at set-point and (4) develop in vitro and in animal models therapies that render the reservoir more susceptible to death through the activation of intrinsic (cellular) and/or extrinsic (virus-specific) pro-apoptotic pathways. This work will leverage our deep investment in (1) the optimization of the SIV NHP model and a humanized mouse model, both developed specifically to support the types of studies we will pursue, (2) the development of a robust clinical cohort (SCOPE) designed to support intensive, biologic studies of people living with HIV (PWH), and (3) the implementation and conduct of several clinical trials designed in part to test our hypotheses in people and from which samples will be made available to our team for ex vivo studies. We anticipate meeting the following milestones and deliverables: (1) definition of the active reservoir in lymphoid tissues from SIV-infected monkeys and HIV-infected humans on effective ART, (2) determination of whether reservoir cells are resistant to intrinsic and extrinsic cell killing, (3) development of a viable and translatable remission strategy in NHPs, and (4) identification and pre-clinical development of interventions aimed at enhancing the cell death, either by making cells more susceptible to cell death and/or by optimizing the efficacy of the virus-specific T cell response.

项目总结/文摘